Quality of Life During Chemotherapy for Breast Cancer in a West African Population in Dakar, Senegal: A Prospective Study

Dano, Domitille; Hénon, Clémence; Sarr, Ousseynou; Ka, Kanta; Bâ, Mouhamadou Bachir; Badiane, Awa Sadikh; Thiam, Ibou; Diene, Papa Massamba; Diop, Mamadou; Dem, Ahmadou; Marino, Patricia; Mancini, Julien; Annède, Pierre; Gonçalvès, Anthony; Diouf, Doudou; Monneur, Audrey

doi:10.1200/jgo.19.00106

Cited by 9 publications

(11 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…While not the primary interest of this study, it is notable that >60% of participants reported at least one grade 3 or higher chemotherapy-related symptom, and >75% of participants reported DT scores ≥4. Chemotherapy adverse event (AE) rates in sub-Saharan African populations are rarely published, but our findings are consistent with the >70% rate of grade 3-5 events at one hospital in Ethiopia and much higher than the ~30% grade 3-4 event rate among breast cancer patients treated in Senegal [35,36]. Self-reported grade 3-4 AEs rates are comparable in high-income countries as well, with two studies from United States and one from Australia reporting rates at 63%, 51% and 62%, respectively [7,37,38].…”

Section: Discussionsupporting

confidence: 86%

Validating an Instrument for Direct Patient Reporting of Distress and Chemotherapy-Related Toxicity among South African Cancer Patients

Blanchard

Mmoledi

Antoni

et al. 2021

Cancers

View full text Add to dashboard Cite

Patient-reported outcome measures (PROM) for monitoring treatment toxicity improve quality of life (QoL) and clinical outcomes. However, no such PROMs exist for sub-Saharan African cancer patients. We aimed to validate the Patient Reported Symptoms-South Africa (PRS-SA) survey, a novel PROM for measuring distress and chemotherapy-related symptoms in South African cancer patients. We enrolled patients at the oncology clinic at Charlotte Maxeke Hospital, Johannesburg. At three separate visits, participants simultaneously completed the PRS-SA survey and several previously validated questionnaires. We constructed a receiver operator characteristics curve for distress levels predicting a Hospital Anxiety and Depression Scale (HADS) score ≥15. We evaluated construct validity for symptom items by comparing severity to the EORTC Core Quality of Life Questionnaire (QLQ-C30) summary score (Pearson correlation tests) and ECOG performance status (Mann–Whitney U tests). We assessed symptom item responsiveness by comparing change in severity to change in QLQ-C30 summary score and comparing standardized mean scores with negative, no, or positive change on the Global Impression of Change (GIC) questionnaire (Jockheere–Terpstra trend test). Overall, 196 participants with solid tumors completed instruments. A distress score of 4 had 82% sensitivity and 55% specificity for clinical depression/anxiety. All symptom items showed construct validity by association with either QLQ-C30 score or performance status (highest p = 0.03). All but cough showed responsiveness to change in QLQ-C30 score (highest p = 0.045). In South African cancer patients, the PRS-SA’s stress scale behaves similarly to the distress thermometer in other populations, and the symptom items demonstrated construct validity and responsiveness. Of note, 46% and 74% of participants who completed the PRS-SA in English or isiZulu, respectively, required assistance reading half or more of the instrument.

show abstract

Section: Discussionsupporting

confidence: 86%

Validating an Instrument for Direct Patient Reporting of Distress and Chemotherapy-Related Toxicity among South African Cancer Patients

Blanchard

Mmoledi

Antoni

et al. 2021

Cancers

View full text Add to dashboard Cite

show abstract

“…When these toxicities occur over a prolonged time and in a greater degree of severity, they may cause the interruption of the treatment [ 9 ]. Moreover, there is a worsening of the quality of life [ 10 , 11 , 12 ] which seems to be associated with a less favorable clinical prognosis and increased risk of recurrence [ 8 ].…”

Section: Introductionmentioning

confidence: 99%

Nutritional Intervention Contributes to the Improvement of Symptoms Related to Quality of Life in Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy: A Randomized Clinical Trial

Souza

Silva²,

Fayh

2021

Nutrients

View full text Add to dashboard Cite

During breast cancer treatment, worsening quality of life (QoL) and the presence of toxicities are common, but healthy eating practices are associated with better clinical results. Thus, this study aims to evaluate the effect of a nutritional intervention on QoL and on gastrointestinal and hematological toxicities resulting from chemotherapy in women with breast cancer. A randomized clinical trial was performed at the beginning of neoadjuvant chemotherapy treatment for women with breast cancer. All participants received nutritional advice on healthy eating practices, but only the intervention group (IG) received an individualized diet plan. The study enrolled 34 women, 19 in the IG and 15 in the control group (CG). During the study, the CG significantly presented a reduction (from 21.6 ± 5.9 kg to 18.8 ± 4.0 kg, p = 0.009) in handgrip strength (HGS), while the IG did not present changes in this variable. Regarding QoL, the IG preserved the role function during treatment and presented better results for nausea/vomiting and loss of appetite compared to the CG. In gastrointestinal and hematological toxicities, the IG had lower frequencies of leukopenia and abdominal pain. The nutritional intervention preserved the role function of QoL and HGS, reduced the occurrence of nausea/vomiting, loss of appetite and the frequency of leukopenia and abdominal pain.

show abstract

“…The majority of the included studies were retrospective studies ( n = 77, 55.8%) of mostly registries and patient files ( 6 , 10 , 24 – 98 ) followed by cross-sectional studies ( n = 51, 36.9%) ( 99 – 149 ), systematic reviews ( n = 5, 3.6%) ( 2 , 150 – 153 ) and reviews ( n = 2, 2.1%) ( 154 , 155 ). There were two prospective studies ( 156 , 157 ) and one modeling study ( 158 ) ( Figure 2 ).…”

Section: Resultsmentioning

confidence: 99%

“…We also found studies conducted in Ghana ( n = 6) ( 50 , 71 , 111 , 123 , 134 , 155 ), Kenya ( n = 5) ( 70 , 96 , 115 , 132 , 139 ), Zambia ( n = 4) ( 44 , 77 , 102 , 126 ), and Eritrea ( n = 3) ( 60 – 62 ). There were seven countries with two studies each [Botswana ( 43 , 47 ), the Central African Republic ( 31 , 32 ), Mozambique ( 57 , 58 ), Rwanda ( 130 , 136 ), Senegal ( 147 , 156 ), Sudan ( 84 , 114 ) and Zimbabwe ( 38 , 39 )]. The countries with a single study were Cote d'Ivoire ( 128 ), Democratic Republic of Congo ( 99 ), Mali ( 85 ), Swaziland ( 76 ), Tanzania ( 49 ), and The Gambia ( 30 ).…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Mapping Evidence on the Burden of Breast, Cervical, and Prostate Cancers in Sub-Saharan Africa: A Scoping Review

Musekiwa

Moyo²,

Mohammed³

et al. 2022

Front. Public Health

View full text Add to dashboard Cite

BackgroundCancer remains a major public health problem, especially in Sub-Saharan Africa (SSA) where the provision of health care is poor. This scoping review mapped evidence in the literature regarding the burden of cervical, breast and prostate cancers in SSA.MethodsWe conducted this scoping review using the Arksey and O'Malley framework, with five steps: identifying the research question; searching for relevant studies; selecting studies; charting the data; and collating, summarizing, and reporting the data. We performed all the steps independently and resolved disagreements through discussion. We used Endnote software to manage references and the Rayyan software to screen studies.ResultsWe found 138 studies that met our inclusion criteria from 2,751 studies identified through the electronic databases. The majority were retrospective studies of mostly registries and patient files (n = 77, 55.8%), followed by cross-sectional studies (n = 51, 36.9%). We included studies published from 1990 to 2021, with a sharp increase from 2010 to 2021. The quality of studies was overall satisfactory. Most studies were done in South Africa (n = 20) and Nigeria (n = 17). The majority were on cervical cancer (n = 93, 67.4%), followed by breast cancer (67, 48.6%) and the least were on prostate cancer (48, 34.8%). Concerning the burden of cancer, most reported prevalence and incidence. We also found a few studies investigating mortality, disability-adjusted life years (DALYs), and years of life lost (YLL).ConclusionsWe found many retrospective record review cross-sectional studies, mainly in South Africa and Nigeria, reporting the prevalence and incidence of cervical, breast and prostate cancer in SSA. There were a few systematic and scoping reviews. There is a scarcity of cervical, breast and prostate cancer burden studies in several SSA countries. The findings in this study can inform policy on improving the public health systems and therefore reduce cancer incidence and mortality in SSA.

show abstract

Quality of Life During Chemotherapy for Breast Cancer in a West African Population in Dakar, Senegal: A Prospective Study

Cited by 9 publications

References 21 publications

Validating an Instrument for Direct Patient Reporting of Distress and Chemotherapy-Related Toxicity among South African Cancer Patients

Validating an Instrument for Direct Patient Reporting of Distress and Chemotherapy-Related Toxicity among South African Cancer Patients

Nutritional Intervention Contributes to the Improvement of Symptoms Related to Quality of Life in Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy: A Randomized Clinical Trial

Mapping Evidence on the Burden of Breast, Cervical, and Prostate Cancers in Sub-Saharan Africa: A Scoping Review

Contact Info

Product

Resources

About